Successful treatment of a patient with adult T-cell leukemia by daily oral administration of low-dose etoposide. Decrease in the amount of HTLV-I proviral DNA revealed by the polymerase chain reaction method
Open Access
- 15 December 1993
- Vol. 72 (12) , 3614-3617
- https://doi.org/10.1002/1097-0142(19931215)72:12<3614::aid-cncr2820721211>3.0.co;2-e
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Infection of rats with HTLV‐1: A small‐animal model for HTLV‐1 carriersInternational Journal of Cancer, 1991
- Major prognostic factors of patients with adult T-cell leukemia-lymphoma: A cooperative studyLeukemia Research, 1991
- Chronic daily administration of oral etoposide in refractory lymphomaEuropean Journal of Cancer and Clinical Oncology, 1990
- Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or EtoposideNew England Journal of Medicine, 1987
- Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer.Journal of Clinical Oncology, 1985
- Establishment and characterization of 10 cell lines derived from patients with adult T-cell leukemia.Proceedings of the National Academy of Sciences, 1983
- Etoposide as a single agent in relapsed advanced lymphomasCancer Chemotherapy and Pharmacology, 1982
- Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphomaProceedings of the National Academy of Sciences, 1980